Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
CHRS Coherus BioSciences
- 1.180
- +0.020+1.72%
Close Feb 14 16:00 ET
136.75MMarket Cap-13.11P/E (TTM)
1.210High1.150Low947.01KVolume1.150Open1.160Pre Close1.12MTurnover0.91%Turnover RatioLossP/E (Static)115.89MShares2.65052wk High-1.55P/B122.73MFloat Cap0.66052wk Low--Dividend TTM104.01MShs Float38.100Historical High--Div YieldTTM5.17%Amplitude0.660Historical Low1.185Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Coherus BioSciences Stock Forum
If you do not vote, its as good as voting against.
gov/Archives/ed...
Top Watch for Monday 1/27
$HOLO (1.56) Inv. Hammer Fri
$HEPA (.19c) Big move com...
📊⚡️📊
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Wednesday, 22nd January at 7:00 am
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate –
– Antitumor activity was observed across both viral and non-viral etiologies –
– Data support continued...
No comment yet